On Tuesday, Harrow cleared an important technical benchmark, with its Relative Strength (RS) Rating climbing into the 80-plus percentile with an improvement to 83, a rise from 72 the day before.
Looking For The Best Stocks To Buy And Watch? Start Here
This exclusive rating from Investor's Business Daily identifies price action with a 1 (worst) to 99 (best) score. The score shows how a stock's price movement over the trailing 52 weeks stacks up against all the other stocks in our database.
Decades of market research reveals that the best-performing stocks tend to have an RS Rating of over 80 as they launch their biggest climbs.
Harrow has risen more than 5% past a 20.31 entry in a third-stage consolidation, meaning it's now out of a proper buy zone. Look for the stock to create a new chance to get in like a three-weeks tight or pullback to the 50-day or 10-week line.
The company showed 0% EPS growth last quarter. Revenue increased 38%. The next quarterly results are expected on or around Aug. 11.
Harrow earns the No. 173 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Incyte and Inhibrx Biosciences are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
